Archives
Multiplex CRISPR: What the Comparisons Show
2026-11-22
Published comparisons support multiplex CRISPR as a flexible platform for coordinated gene disruption, structural-variant modeling and combinatorial regulation, but they do not establish a universal advantage across cell types, targets or delivery systems. The strongest conclusions concern mechanism and feasibility; specificity, delivery, toxicity and clinical applicability remain context-dependent.
Adamtsl3, MMP9 and Adult Cortical Plasticity
2026-11-21
A mechanistic interpretation of how Adamtsl3 regulates perineuronal nets, MMP9 activity, PV-interneuron state and ocular-dominance plasticity in mouse visual cortex, with attention to pharmacological rescue, evidence strength and translational limits.
How Adamtsl3 Constrains MMP9-Driven Plasticity
2026-11-20
A mechanistic analysis of how Adamtsl3 regulates MMP9, perineuronal-net integrity, and adult visual-cortex plasticity, with attention to what SB-3CT-associated pharmacology can and cannot establish.
Context Determines What an MMP Rescue Means
2026-11-20
How SB-3CT’s gelatinase profile, mouse visual-cortex models, and downstream readouts alter the causal interpretation of Adamtsl3–MMP9 research.
Adamtsl3, MMP9 and Cortical Plasticity
2026-11-19
A mouse study identifies Adamtsl3 as a parvalbumin-interneuron-associated regulator of perineuronal-net stability in visual cortex. Its findings connect Adamtsl3 loss to elevated MMP9 activity, altered extracellular-matrix composition, oxidative stress and renewed adult ocular-dominance plasticity, while pharmacological rescue supports—but does not by itself prove—a direct MMP9 mechanism. SB-3CT is relevant as a documented MMP-2/MMP-9 pathway probe, not as confirmed evidence of efficacy in this study.
What the Evidence Shows—and Leaves Unresolved
2026-11-19
A paper-centered analysis separates the documented biochemical role of a high-fidelity PCR reagent from the preclinical evidence for a calcium-lactate, bufalin and CD47-directed CRISPR nanomedicine.
Adamtsl3, MMP9 and Cortical Plasticity
2026-11-18
A mouse visual-cortex study identifies Adamtsl3 as a cell-autonomous regulator of perineuronal nets around parvalbumin interneurons. Its genetic and pharmacological evidence connects Adamtsl3 loss to MMP9 activity, extracellular-matrix remodeling, altered Otx2 uptake, oxidative stress and renewed adult ocular-dominance plasticity, while leaving important questions about inhibitor selectivity and human disease relevance.
A Targeted Strategy for High-Yield Rabbit Pharming
2026-11-18
A 2025 study used targeted insertion at the endogenous CSN2 locus to create rabbits producing 15–20 g/L of the reporter protein tdTomato in milk. The result is a strong proof of concept for locus-directed expression, but its broader relevance depends on protein-specific behavior, animal-level productivity, product quality, and reproducibility beyond the reported founders.
What Gene Maps Reveal About the Claustrum
2026-11-17
A comparative study argues that dorsal and ventral claustrum compartments and the dorsal endopiriform nucleus retain recognizable molecular and topological relationships across mammals, despite major changes in size and shape. The evidence strengthens anatomical comparison but does not by itself establish functional equivalence, causal gene roles, or direct translation to humans.
SB-3CT, MMP9, and Adult Cortical Plasticity
2026-11-17
A mouse visual-cortex study links Adamtsl3 loss in parvalbumin interneurons to MMP9 hyperactivity, perineuronal-net disruption, and renewed adult ocular-dominance plasticity. SB-3CT provides a gelatinase-directed pharmacological context for interpreting that pathway, but its activity against both MMP-2 and MMP-9 limits claims of MMP9-exclusive causality or therapeutic relevance.
Adamtsl3, MMP9 and Cortical Plasticity
2026-11-16
A mouse visual-cortex study identifies Adamtsl3 as a parvalbumin-interneuron regulator of perineuronal nets and places MMP9 activity between extracellular-matrix disruption and renewed adult cortical plasticity. SB-3CT is best interpreted as a pharmacological gelatinase-inhibition tool within that mechanistic framework, not as evidence that all reported outcomes arise from one compound.
Adamtsl3, MMP9 and Cortical Plasticity
2026-11-16
A mouse visual-cortex study identifies Adamtsl3 as a cell-autonomous regulator of perineuronal nets around parvalbumin interneurons. Its genetic, biochemical, imaging and electrophysiological evidence places extracellular MMP9 downstream of Adamtsl3 loss, while pharmacological inhibition supports—but does not by itself prove—a causal MMP9 mechanism.
When Context Changes What SB-3CT Shows
2026-11-15
A result obtained with SB-3CT means different things in a cortical plasticity model, a metastasis model, or an ischemia model. The key distinction is between evidence that implicates MMP9 in a mechanism and evidence that establishes compound-specific efficacy.
SB-3CT and the MMP9–PNN Evidence Gap
2026-11-14
Published mouse data connect Adamtsl3 loss, MMP9 hyperactivity, perineuronal-net disruption, and adult visual-cortex plasticity. The findings support MMP9 as a mechanistic contributor, but they do not establish that SB-3CT is MMP9-specific in vivo or that the cortical phenotype is transferable to cancer metastasis or human neuropsychiatric disease.
When Context Changes What a Result Means
2026-11-13
A mouse visual-cortex study shows how Adamtsl3, MMP9 activity, perineuronal-net integrity, and adult cortical plasticity can be linked mechanistically. The same gelatinase inhibitor has a different evidentiary meaning in tumor metastasis research or cerebral-ischemia models, where the biological context and readouts are not interchangeable.